Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients [PDF]
Frontiers in PediatricsObjectiveTo comprehensively compare the efficacy and safety of long-acting human growth hormone (LAGH) preparations with conventional short-acting daily growth hormone (SA-GH) in children with isolated growth hormone deficiency (GHD), and explore ...
Zhen-Zhen Shen +4 more
doaj +2 more sources
New directions in growth hormone treatment in children [PDF]
Pediatric Endocrinology, Diabetes and MetabolismThis paper reviews clinical-trial evidence on the use of long-acting growth hormone (LAGH) preparations in children. Three LAGH products have been approved in Europe and the United States for paediatric growth hormone deficiency (GHD): lonapegsomatropin,
Renata Stawerska
doaj +2 more sources
Long-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency [PDF]
Annals of Pediatric Endocrinology & MetabolismLong-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric GH deficiency, offering an alternative to daily recombinant human GH (rhGH) therapy.
Chiara Rodaro +3 more
doaj +2 more sources
Detection of the GH analog somatrogon in sports drug testing: Immunological approaches and LC-HRMS/MS. [PDF]
Drug Test AnalThe detectability of the GH analog somatrogon with approved doping control immunoassays for hGH and hCG was evaluated and a both sensitive and specific qualitative detection assay employing affinity purification, tryptic digestion, and LC‐HRMS/MS was developed to confirm the presence of the drug in suspicious serum samples. Abstract Due to the presumed
Walpurgis K +5 more
europepmc +2 more sources
Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections [PDF]
Medical Devices: Evidence and ResearchShahid Akhtar,1 Birgitte Berg,2 Johan Medina,3 Maya Nicole Gonczi,4 Sophie Hamilton,5 Emily Hildebrand,4 Nicky Kelepouris,6 Jesper Skov Neergaard,7 Claus Sværke,8 Gitte Ter-Borch,2 Niklas Kahr Rasmussen3 1Devices & Digital Health, Novo Nordisk A/S ...
Akhtar S +10 more
doaj +2 more sources
Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025. [PDF]
Drug Test AnalNew insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Thevis M, Kuuranne T, Geyer H.
europepmc +2 more sources
Severe Lipoatrophy in a Growth Hormone Deficient Toddler Girl Treated with a Non-Pegylated Long-Acting Growth Hormone [PDF]
ChildrenBackground: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat,
Atilla Büyükgebiz, And Demir
doaj +2 more sources
Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency
Expert Review of Pharmacoeconomics and Outcomes Research, 2023 To analyze the cost-effectiveness of weekly somatrogon compared to daily growth hormones (GH-d) in the pediatric population of Spain with growth hormone deficiency (GHD).Markov model with two states (patients with or without GH-d or somatrogon treatment) in prepubertal children (3 to 11 years and 3 to 12 years in girls and boys, respectively) with GHD ...
D Rubio-Rodríguez, C Rubio-Terres
exaly +4 more sources
Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis [PDF]
Scientific ReportsThe purpose of this study is to compare the relative efficacy and safety of long-acting growth hormone (LAGH) as a growth hormone replacement therapy in prepubertal children with growth hormone deficiency (GHD).
Jianfang Zhu +6 more
doaj +2 more sources
First 100 patients receiving long-acting growth hormone therapy: real-world evaluation from INSIGHTS-GHT registry [PDF]
Orphanet Journal of Rare DiseasesThe development of long-acting growth hormone (LAGH) formulations offers a promising approach to reduce injection frequency and to improve adherence in growth hormone deficiency (GHD) treatment.
Joachim Woelfle +5 more
doaj +2 more sources